IngredientesBranched-chain amino acids (BCAAs) are a group of three essential aliphatic amino acids defined by the presence of a branched side chain — a central carbon atom bound to three or more additional carbon atoms — on their molecular structure. A branched-chain amino acid (BCAA) is an amino acid having an aliphatic side-chain with a branch, and among the proteinogenic amino acids there are three BCAAs: leucine, isoleucine, and valine.
Their systematic and common chemical names are:
The three proteinogenic BCAAs are among the nine essential amino acids for humans, accounting for 35% of the essential amino acids in muscle proteins and 40% of the preformed amino acids required by mammals.
The BCAAs are nutritionally essential in that they cannot be synthesized endogenously by humans and must be supplied by diet. They differ from other essential amino acids in that the liver lacks the enzymes necessary for their catabolism. Unlike most amino acids, which are primarily oxidized in the liver, BCAAs are predominantly metabolized in skeletal muscle and other peripheral tissues.
BCAAs are synthesized in bacteria, plants, and fungi, but not in animals. The synthesis of valine and isoleucine is carried out by the same enzymes, and leucine is created from α-ketoisovalerate, a transamination precursor of valine. The carbons in valine (and leucine) are derived from the readily available and abundant pyruvate, but isoleucine carbons are derived from the relatively rare threonine. Because BCAA synthesis does not occur in animals, it has been successfully targeted for antimicrobials, herbicides, and antifungal agents.
Dietary sources of BCAAs include red meat, dairy products, chicken, fish, and eggs. The main food sources of BCAAs in the US population were meat (37%), milk (12%), and fish (8%), while in the Japanese population the main contributors were cereals, potatoes and starches (23–25%), fish and shellfish (21–23%), and meat (14–15%). Plant-based sources may also contain BCAAs, but often in lower amounts compared to animal sources. Soy products such as tempeh, edamame, and tofu are considered complete protein sources and contain all the essential amino acids in sufficient quantities, including BCAAs.
BCAA supplements are produced primarily via microbial fermentation. Industrial synthesis of BCAAs, particularly using bacterial strains like Corynebacterium glutamicum, is a major production method, alongside genetic engineering aimed at enhancing fermentation yield, involving detailed enzymatic processes and specific precursors. Traditional industrial fermentative production of BCAAs was performed using microorganisms isolated by random mutagenesis.
Supplement forms on the market include:
Commercial BCAA powders are sold in differing leucine:isoleucine:valine ratios. The 2:1:1 ratio indicates a composition of 2 parts leucine to 1 part isoleucine and 1 part valine; this formulation is considered the closest to the proportion naturally present in human muscles. The 4:1:1 ratio contains 4 parts leucine to 1 part isoleucine and 1 part valine, emphasizing leucine, which is recognized as the most important amino acid for stimulating muscle protein synthesis. BCAAs are also added to many multi-ingredient products, including pre-workout supplements.
Scientists discovered branched-chain amino acids in the mid-1800s and have studied them intensively since. They know that BCAAs are important for many body functions, but there is much more for science to investigate. First identified and isolated in the early twentieth century, BCAAs have since been the focus of extensive research, especially due to their increasing importance in health and disease.
BCAAs have been studied in a number of muscle wasting disorders for more than 50 years. Their formal therapeutic investigation began primarily within clinical nutrition research in the mid-twentieth century, with early focus on conditions of metabolic stress such as surgery, trauma, and liver disease. Unlike many botanical dietary supplements with ancient folk-medicine traditions, BCAAs do not have a discrete traditional herbal history; their use is grounded in the identification of essential amino acid deficiency states and the clinical observation that patients with liver cirrhosis exhibit markedly altered plasma amino acid profiles. In patients with advanced chronic liver disease, BCAA concentrations are low, whereas the concentrations of aromatic amino acids (AAA) such as phenylalanine and tyrosine are high, conditions that may be closely associated with hepatic encephalopathy.
In the past, BCAAs were predominantly used by powerlifters and the bodybuilding community, but BCAAs are becoming progressively adopted across the wider athletic population. The growth of sports nutrition as an industry from the 1980s onward substantially drove consumer interest in BCAA supplementation, and a multi-million dollar industry of nutritional supplements has grown around the concept that dietary supplements of BCAAs alone produce an anabolic response in humans driven by a stimulation of muscle protein synthesis.
BCAA supplements contain varying proportions of three pure amino acids: L-leucine, L-isoleucine, and L-valine. Each has a distinct metabolic fate and a distinct set of physiological roles.
Leucine is widely regarded as the dominant anabolic signal among the three BCAAs. Of the three BCAAs, leucine is primarily responsible for the stimulation of protein synthesis. The stimulatory effect of leucine on protein synthesis is mediated through upregulation of the initiation of mRNA translation. A number of mechanisms, including phosphorylation of ribosomal protein S6 Kinase, eukaryotic initiation factor (eIF)4E binding protein-1, and eIF4G, contribute to the effect of leucine on translation initiation. Leucine serves as substrate for the synthesis of new muscle proteins and as a signal to initiate the rate-limiting translation initiation step of muscle protein synthesis (MPS).
Isoleucine catabolism ultimately yields propionyl-CoA and acetyl-CoA. Isoleucine is considered both glucogenic and ketogenic. Isoleucine has been noted to promote glucose transport into skeletal muscle cells and plays supporting roles in energy metabolism and immune function.
Valine (5C) loses 2 carbons to COâ‚‚ and contributes 3 carbons to the TCA cycle as succinyl-CoA. Valine is considered glucogenic (i.e., succinyl-CoA is anaplerotic). Valine participates in energy generation and nitrogen shuttling in muscle tissue.
As the most abundant of essential amino acids, BCAAs are not only substrates for synthesis of nitrogenous compounds; they also serve as signaling molecules regulating metabolism of glucose, lipid, and protein synthesis, intestinal health, and immunity via special signaling networks, especially the phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) signal pathway.
BCAAs, particularly leucine, have anabolic effects on protein metabolism by increasing the rate of protein synthesis and decreasing the rate of protein degradation in resting human muscle. During recovery from endurance exercise, BCAAs have also been found to have anabolic effects in human muscle. These effects are mediated through changes in signaling pathways controlling protein synthesis, involving phosphorylation of the mammalian target of rapamycin (mTOR) and sequential activation of 70-kD S6 protein kinase (p70 S6 kinase) and eukaryotic initiation factor 4E-binding protein 1.
Leucine treatment enhances the phosphorylation of mTOR, and its activation up-regulates protein translation through the phosphorylation of the eukaryotic initiation factor 4E binding protein 1 (4E-BP1) and the ribosomal protein S6 kinase (S6K), leading to cell growth and proliferation.
In addition to being used as substrates for protein synthesis, BCAAs can stimulate skeletal muscle protein synthesis and suppress proteolysis. Beyond their function as structural components of proteins, BCAAs exert regulatory control of protein metabolism. In rodent tissue in vitro, increased concentrations of BCAAs stimulate protein synthesis and inhibit protein catabolism, whereas other amino acid mixtures lacking BCAAs have no such influence.
The reversible transamination reactions yield branched-chain α-keto acids (BCKAs) from leucine, isoleucine, and valine respectively. The BCKAs are then irreversibly oxidatively decarboxylated by the branched-chain keto acid dehydrogenase (BCKDH) complex to produce corresponding acyl-CoA derivatives. The BCKDH reaction is the rate-limiting step in BCAA catabolism and is therefore tightly regulated.
Crucial roles in BCAA metabolism are played by: (i) skeletal muscle as the initial site of BCAA catabolism accompanied with the release of alanine and glutamine to the blood; (ii) activity of branched-chain keto acid dehydrogenase (BCKD); and (iii) amination of branched-chain keto acids to BCAAs.
BCAAs share the same transport protein into the brain with aromatic amino acids (Trp, Tyr, and Phe). Once in the brain, BCAAs may have a role in protein synthesis, synthesis of neurotransmitters, and production of energy. This competition for transport across the blood-brain barrier forms the basis of the Fischer ratio theory used to explain the relationship between BCAA deficiency and hepatic encephalopathy.
BCAAs are broken down effectively by dehydrogenase and decarboxylase enzymes expressed by immune cells, and are required for lymphocyte growth and proliferation and cytotoxic T lymphocyte activity.
Clinical Evidence: One human study directly measuring post-exercise muscle protein synthesis found that myofibrillar-MPS was 22% higher in the BCAA group (0.110 ± 0.009%/h) than placebo (0.090 ± 0.006%/h; P = 0.012). Phenylalanine Ra was approximately 6% lower in the BCAA group than placebo after drink ingestion. The authors concluded that ingesting BCAAs alone increases the post-exercise stimulation of myofibrillar-MPS and phosphorylation status of mTORC1 signaling.
When BCAAs were supplied to subjects during and after one session of quadriceps muscle resistance exercise, an increase in mTOR, p70 S6 kinase, and S6 phosphorylation was found in the recovery period after exercise.
Critical Appraisal: Despite these mechanistic findings, the broader clinical picture for muscle hypertrophy is less clear. A multi-million dollar industry has grown around the concept that dietary supplements of BCAAs alone produce an anabolic response in humans driven by a stimulation of muscle protein synthesis. The theoretical and empirical bases for that claim have been critically examined in the literature. A key limitation often raised is that BCAAs alone lack the full complement of essential amino acids needed to maximally stimulate net muscle protein balance. Research does not offer strong evidence for the use of BCAAs to increase muscle mass, and BCAA supplements may be no better for muscle growth and recovery than BCAAs from dietary sources.
Evidence Strength: Moderate-to-low for muscle hypertrophy; mechanistic evidence (mTOR activation) is well established, but net anabolic effects in well-nourished individuals consuming adequate dietary protein are uncertain.
Clinical Evidence: Multiple systematic reviews and meta-analyses of RCTs have investigated BCAAs for reducing exercise-induced muscle damage (EIMD) markers and delayed-onset muscle soreness (DOMS). Nine studies met inclusion criteria in one 2021 meta-analysis. A positive effect was found for creatine kinase (CK) at <24, 24, and 48 hours after exercise, and for muscle soreness at <24 hours only. However, the positive effect was not evident for plasma LDH at any follow-up time. Different outcomes for post-exercise responses may suggest that BCAA supplementation can attenuate muscle damage and ameliorate muscle soreness after resistance exercise in trained males.
A more recent 2024 meta-analysis with meta-regression reported that of the 18 studies included, 13 were of high quality and five were of acceptable quality. BCAA supplementation elicited a significant effect on reducing creatine kinase (CK) levels immediately (g = −0.44; p = 0.006) and at 72 hours (g = −0.99; p = 0.002), but not at 24, 48, and 96 hours post-EIMD.
Evidence Strength: Moderate. There is consistent but variable evidence that BCAAs reduce short-term markers of muscle damage and early soreness. Effects on lactate dehydrogenase and longer-term soreness are less consistently demonstrated. Most trials are small and use differing dosing protocols, populations, and exercise modalities.
Clinical Evidence: This is among the most extensively studied clinical applications of BCAAs, supported by multiple Cochrane systematic reviews. A Cochrane review found 16 randomised clinical trials including 827 participants with hepatic encephalopathy classed as overt (12 trials) or minimal (four trials). Eight trials assessed oral BCAA supplements and seven trials assessed intravenous BCAA. The evidence suggests BCAAs reduce hepatic encephalopathy, but the certainty of evidence is low. The review found no known effect of BCAAs on all-cause mortality, nausea and diarrhoea, albumin, and nitrogen balance because of very low-certainty evidence.
The 2026 updated Cochrane review confirmed that BCAAs did not affect mortality but had a beneficial effect on hepatic encephalopathy.
Earlier quantitative analyses also confirmed the signal: BCAAs significantly increased the number of patients improving from hepatic encephalopathy compared with control treatments (59% vs. 41%; risk ratio, 1.31; 95% CI, 1.04–1.66), without any convincing evidence for an effect on survival or adverse events. The review was based on 11 randomized trials (556 patients). The median amount of BCAAs administered was 28 g/d (range 11–57 g), and the median duration of treatment was 7 days (range 4–90 days).
Regarding clinical guidelines: The 2014 joint guidelines from the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) recommend treatment of any precipitating factors and non-absorbable disaccharides as the initial treatment, and recommend BCAAs as an alternative or additional agent to treat people who do not respond to the initial therapy.
In a large multicenter trial, Muto et al. conducted a multicenter, randomized, nutrient-intake-controlled trial on the comparative effects of BCAA orally administered at 12 g/day for 2 years vs. non-BCAA-supplemented diet therapy, in 646 patients with cirrhosis.
For sarcopenia specifically complicating liver cirrhosis, a randomized clinical trial (the BCAAS Study) found that treatment with BCAA led to significant improvement in sarcopenic parameters, such as muscle strength, muscle function, and muscle mass. Total cirrhotic-related complications and cumulative event-free survival occurred fewer in the BCAA group than in the control group. The study concluded that long-term BCAA supplementation improved sarcopenia and prognostic markers in patients with advanced liver cirrhosis.
Evidence Strength: Moderate for symptom reduction of overt hepatic encephalopathy; low certainty for mortality, quality of life, and nutritional outcomes. No head-to-head trials exist to compare the effect of BCAAs with non-absorbable disaccharides (lactulose), rifaximin, or other antibiotics.
Clinical Evidence: Sarcopenia — the progressive loss of skeletal muscle mass and function with aging — is an area of active BCAA research. A study evaluating enriched BCAA supplementation in subjects with pre-sarcopenia or sarcopenia (ClinicalTrials.gov Identifier: NCT03891134) hypothesized that physical performance, muscle strength, and muscle mass of elderly patients would improve after 5 weeks of treatment with enriched BCAAs. The 33 participants had a mean age of 66.6 ± 10.3 years.)
One clinical trial found that supplementation with BCAAs combined with resistance exercise significantly enhanced muscle mass and strength. BCAAs are considered more effective in combating sarcopenia by reducing cortisol levels, promoting muscle repair, and creating a synergistic effect with resistance training.
However, the evidence is inconsistent: a meta-analysis came to the opposite conclusion, indicating that BCAA alone were not effective in improving muscle health. Other studies also show that BCAA supplements do not enhance protein synthesis or improve muscle strength, mass, or physical performance.
A double-blind RCT in older sarcopenic patients (N = 140; ≥65 years; mean age 81 ± 6 years) hospitalized for rehabilitation found that a whey protein-based nutritional formula enriched with leucine and vitamin D improved physical performance and function, as well as muscle mass, and reduced the intensity and costs of care. This study used a leucine-enriched protein formulation rather than isolated BCAAs, an important distinction for interpretation.
Evidence Strength: Mixed and inconclusive. Isolated BCAA supplementation in older adults shows inconsistent effects on muscle mass and function; combination with exercise and adequate total protein intake appears more promising. Leucine-enriched protein formulas show more consistent benefit.
BCAAs have been explored as a nutritional adjunct in TBI based on their role in brain amino acid metabolism and neurotransmitter precursor availability. BCAAs share the same transport protein into the brain with aromatic amino acids and may have roles in protein synthesis, synthesis of neurotransmitters, and production of energy once in the brain. BCAAs are nutritionally essential and cannot be synthesized by humans. They differ from other essential amino acids in that the liver lacks the enzymes for their catabolism. In addition to their function as structural components of proteins, BCAAs also exert regulatory control of protein metabolism.
A clinical trials protocol assessing BCAAs in concussion noted that a single dose-finding study in 12 healthy volunteers showed in a randomized, double-blind, crossover design that single oral doses of 10 g, 30 g, and 60 g of BCAAs were safe and well tolerated. Evidence in this area remains preliminary and mostly from smaller trials.
Evidence Strength: Preliminary. Larger, well-powered RCTs specifically in TBI are needed before firm conclusions can be drawn.
BCAAs are known to promote skeletal muscle growth in healthy individuals; however, their efficacy in cancer patients remains controversial. In both a mouse cachexia model and an in vitro cachexia model, BCAAs did not significantly reduce oxidative stress, improve oxidative phosphorylation, suppress cytokine production, or enhance muscle mass and maturation, as observed in non-cancer-bearing models. Despite growing interest in the role of amino acids in skeletal muscle preservation, the specific mechanisms and clinical effectiveness of BCAA in cancer cachexia remain insufficiently explored.
BCAAs are gaining attention for their potential therapeutic uses, including improving appetite in cancer patients.
Evidence Strength: Preliminary to insufficient. The preclinical data are mixed and there is a lack of adequately powered human clinical trials specifically in cancer cachexia.
Current evidence supports BCAAs and their derivatives as potential biomarkers of diseases such as insulin resistance, type 2 diabetes mellitus (T2DM), cancer, and cardiovascular diseases. Elevated circulating BCAA concentrations have been associated with these metabolic conditions, though causality is not established. Elevated BCAA concentrations are associated with obesity, insulin resistance, and type 2 diabetes mellitus, while low BCAA plasma levels are correlated with the prevalence of liver cirrhosis and hepatic encephalopathy, and shifts in BCAA metabolism have been linked to tumor growth, progression, and survival.
The results from previous studies have suggested that increased BCAA catabolic flux may contribute to increased gluconeogenesis and glucose intolerance via glutamate transamination to alanine.
Evidence Strength: The epidemiological and biomarker associations are replicated, but they do not establish that BCAA supplementation causes or remedies these conditions. Whether elevated circulating BCAAs are causal or merely a biomarker of metabolic dysfunction remains under investigation.
BCAAs are associated with the following physiological systems based on the peer-reviewed literature:
The Food and Nutrition Board (FNB) of the U.S. Institute of Medicine set Recommended Dietary Allowances (RDAs) for essential amino acids in 2002. For leucine, for adults 19 years and older: 42 mg/kg body weight/day; for isoleucine: 19 mg/kg body weight/day; for valine: 24 mg/kg body weight/day. For a 70 kg person this equates to 2.9, 1.3, and 1.7 g/day respectively.
Doses used in clinical studies vary substantially by indication:
Branched-chain amino acid supplements are considered safe when taken in proper doses for short periods of time. As far as researchers have observed, BCAAs cause very few adverse effects. BCAAs may cause side effects such as fatigue and loss of coordination. BCAAs should be used cautiously before or during activities that require motor coordination, such as driving.
The most common side effects revealed during clinical trials were gastrointestinal: decreased appetite, anorexia, nausea, and general stomach discomfort.
On upper-limit guidance: the NIH Office of Dietary Supplements notes that up to 20 g/day in divided doses appears to be safe in the studies they reviewed, while also flagging that long-term safety data is limited.
BCAAs may interact with medications, including thyroid hormones, drugs for Parkinson's, and medicines for diabetes.
An Italian ALS Study Group trial examined high-dose BCAAs at 12 g three times daily in ALS patients. The trial was discontinued early due to an accelerated rate of respiratory muscle decline and higher mortality in the BCAA supplementation arm versus placebo. The mechanism underlying this adverse outcome remains debated — hypotheses include excitotoxicity via glutamate pathway dysregulation. While standard supplementation doses (5–20 g/day) in healthy individuals are very different from the extreme doses used in this trial, the unresolved mechanistic concern and the severity of the observed adverse outcome justify caution against BCAA supplementation in any form of motor neuron disease.
Supporting the concern from animal data: certain studies suggested a possible link between a high incidence of ALS among professional American football players and Italian soccer players and certain sports supplements including BCAAs. In mouse studies, BCAAs were shown to cause cell hyper-excitability resembling that usually observed in ALS patients.
Increased BCKD activity is responsible for enhanced oxidation of BCAAs in chronic renal failure, trauma, burn, sepsis, cancer, and phenylbutyrate-treated subjects, as well as during exercise. In states of chronic renal failure, BCAA catabolism is dysregulated, and supplementation in these populations requires individualized clinical assessment.
A deficiency of the BCKDH complex leads to a buildup of the branched-chain amino acids and their toxic by-products in the blood and urine, giving the condition the name maple syrup urine disease. Individuals with MSUD or related inborn errors of BCAA metabolism must restrict BCAA intake and should not use standard BCAA supplements.
Restriction of dietary BCAAs extends lifespan in flies, while restriction of BCAAs in mice extends male lifespan and decreases frailty but does not extend female lifespan. In mice, dietary supplementation with BCAAs alone decreases lifespan and promotes obesity. These animal findings cannot be directly translated to humans but underscore the complexity of BCAA biology beyond the simple anabolic narrative.
The FDA has not reviewed BCAAs for safety and effectiveness as dietary supplements. BCAAs are dietary supplements and cannot be marketed to treat or cure a disease.
Condiciones de salud que BCAA puede ayudar a apoyar.
BCAAs (leucine, isoleucine, valine) are strongly supported by multiple meta-analyses for reducing exercise-induced muscle damage markers, attenuating DOMS, and improving strength recovery post-exercise compared to placebo or passive rest. Acute supplementation at 0.087 g/kg has shown increased recovery of isometric strength and CMJ height.
Sistemas corporales que BCAA puede ayudar a apoyar.
Volver